Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "cost"

1356 News Found

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer
Biopharma | May 19, 2026

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs


India’s opportunity to build preventive healthcare economy
Opinion | May 19, 2026

India’s opportunity to build preventive healthcare economy

The country’s strength lies not just in technology availability but in adoption behaviour


Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle
News | May 19, 2026

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine


Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare
interviews | May 18, 2026

Precision oncology must be decentralized to reach every patient: Dr Vidya Veldore, Vice President, Clinical Operations, 4baseCare

Access to genomic testing, not therapy cost, is the biggest challenge


Amrutanjan Healthcare expands portfolio in pain management
News | May 18, 2026

Amrutanjan Healthcare expands portfolio in pain management

Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil


Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%
News | May 18, 2026

Akums Q4 revenue climbs to Rs. 1,158 crore; PAT surges 135%

FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies


Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26
News | May 18, 2026

Gland Pharma posts record revenue, nearly doubles profit in Q4 FY26

The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment


Kotak Alts invests Rs. 200 million in Cellogen Therapeutics
Biopharma | May 18, 2026

Kotak Alts invests Rs. 200 million in Cellogen Therapeutics

Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities